Reversing fibrosis at scale in Steatotic Liver Disease.
Steatotic Liver Disease
KRIYA.497 is a one-time investigational gene therapy designed to express native FGF21, with a goal of reversing fibrosis and steatosis as well as improving the overall metabolic profile in patients with steatotic liver disease.
Steatotic liver disease is a progressive condition in which excess fat builds up in the liver, driving inflammation and fibrosis over time. As it advances, healthy liver tissue is gradually replaced by scarring, which can progress to cirrhosis, liver failure, and liver cancer. It is one of the most common reasons for liver transplantation in the U.S.
KRIYA.497
How it works
The pathophysiology of steatotic liver disease is driven by metabolic dysfunction; processes FGF21 helps regulate. KRIYA.497 is designed to express the native human form of the FGF21 protein in a steady and continuous manner. The goal is to achieve long-lasting and stable levels of FGF21 for engagement in FGF21-responsive tissues that can reverse fibrosis in the liver.
Loading…
Failed to load vial.
Specifications
| Indication | Steatotic liver disease |
|---|---|
| Modality | AAV-based gene therapy |
| Mechanism | Metabolic regulation |
| Payload | Native FGF21 protein |
| Delivery | Intramuscular injection, outpatient |
| Dosing frequency | Single administration |
| Potential patient impact | ~40 million, US and EU |
| Stage | Phase 1/2 |
Disclaimer
Kriya’s durable medicines are investigational and have not been approved as safe or effective by any regulatory health authority.
